… Shortly after that, the efficacy of Anakinra in the treatment of a colchicine resistant 68 year
old woman homozygous for the M694 V mutation of the MEFV gene [43] and a 15 year-old …

… one-fifth of the patients are children and adolescents. Out of 463 MEFV mutation-specified …
trial to explore the safety and efficacy of anakinra in colchicine-resistant FMF patients. It was …

… Twenty-seven per cent of patients were previously treated with biologics, mainly anakinra. …
associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann …

… -1 receptor antagonist anakinra for colchicine-resistant FMF … series of colchicine-resistant
Familial Mediterranean fever patients … nine adolescent and adult FMF patients. They treated the …

… trial with anakinra in FMF patients who were colchicine resistant was published (…
colchicine-resistant familial Mediterranean fever. They also showed that IL-1 inhibition is an …

… achieved good outcomes about effectiveness and safety [20]. Anakinra and canakinumab
are … Anakinra and canakinumab succeeded in complete remission in more than two-third of …

… Anakinra is proven to be effective in controlled trials in terms of attack frequency and subclinical
inflammation in colchicine-resistant … The effectiveness of anakinra stems from preventing …

… Anakinra in two adolescent female patients suffering from colchicine-resistant familial
Mediterranean fever: … H, TÜRKMEN A, GÜL A: Efficacy of anakinra treatment in a patient with …

… in the prevention of attacks in patients with colchicine-resistant FMF (crFMF) or colchicine-intolerant
FMF. Interleukin 1 antagonists, anakinra, canakinumab, and rilonacept, have been …

… and safety of canakinumab in children and adolescents-young adults [11, 15]. In both studies,
… of colchicine-resistant patients, its efficacy for clinical findings and its cost effectiveness will …